argenx (ARGX) vs Biogen (BIIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biogen (BIIB) has outperformed argenx (ARGX) over the past year, gaining 44.7% versus a gain of 2.5%. Over five years, ARGX leads with a +178.7% price change compared with -22.3% for BIIB. argenx is the larger company by market cap ($51.48 billion vs $32.27 billion), about 1.6 times the size.
On valuation, Biogen trades at a lower forward P/E (13.2x vs 23.6x for argenx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | BIIB |
|---|---|---|
| Share price | $818.63 | $218.43 |
| Market cap | $51.48B | $32.27B |
| 1-day change | -11.83% | -1.67% |
| YTD return | -2.65% | +24.12% |
| 1-year return | +2.46% | +44.68% |
| 5-year return | +178.69% | -22.32% |
| P/E ratio (TTM) | 31.20 | 38.80 |
| Forward P/E | 23.58 | 13.22 |
| EPS (TTM) | $26.24 | $5.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.89B |
| Revenue growth (YoY) | — | +2.22% |
| Net income (latest FY) | $1.29B | $1.29B |
| Gross margin | — | 75.69% |
| Net margin | — | 13.07% |
| 52-week high | $1,072.75 | $230.49 |
| 52-week low | $661.85 | $138.00 |
| Distance from 52-week high | -23.69% | -5.23% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +43.17% | +9.04% |
| Average volume | 283.40K | 1.06M |
| Shares outstanding | 62.89M | 147.75M |
| Employees | 1,863 | 7,500 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIIB has outperformed ARGX by 42.2 percentage points over the past year.
- The two companies sit in different sectors: argenx in Healthcare and Biogen in Health Care.
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Healthcare · Biotechnology · 1,863 employees
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
ARGX vs BIIB FAQ
Which is bigger, argenx or Biogen?
argenx (ARGX) is larger, with a market capitalization of $51.48B compared with $32.27B for Biogen (BIIB).
Which stock has performed better over the past year, ARGX or BIIB?
BIIB returned +44.68% over the past 12 months, compared with +2.46% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARGX or BIIB?
ARGX has the lower trailing P/E at 31.2, versus 38.8 for BIIB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are argenx and Biogen in the same industry?
No. argenx is in the Healthcare sector, while Biogen is in Health Care.